SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectations

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) is suited for growth investing. Investors should of course do their own research, but we spotted SAREPTA THERAPEUTICS INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

A Deep Dive into SAREPTA THERAPEUTICS INC's Growth Metrics.

• In terms of Return on Equity(ROE), SAREPTA THERAPEUTICS INC is performing well, achieving a 15.4% ratio. This highlights the company's effective allocation of shareholder investments and signifies its commitment to maximizing returns.
• SAREPTA THERAPEUTICS INC has a strong history of beating EPS estimates 3 times in the last 4 quarters, signaling its ability to consistently exceed market expectations. This indicates the company's strong financial performance and its potential for creating shareholder value.
• SAREPTA THERAPEUTICS INC has demonstrated strong 1-year revenue growth of 52.98%, reflecting revenue momentum and its ability to generate consistent top-line expansion. This growth underscores the company's strong market position and its potential for future success.
• The quarter-to-quarter (Q2Q) revenue growth of 65.94% of SAREPTA THERAPEUTICS INC has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and drive revenue growth.
• SAREPTA THERAPEUTICS INC has experienced notable growth in its operating margin over the past year, reflecting improved operational performance. This growth suggests the company's ability to generate higher profits from its core business activities.
• With a favorable trend in its free cash flow (FCF) over the past year, SAREPTA THERAPEUTICS INC demonstrates its ability to generate robust cash flows and maintain financial stability. This growth reflects the company's focus on efficient capital allocation and cash management.
• In the most recent financial report, SAREPTA THERAPEUTICS INC reported a 219.0% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
• Over the past 3 months, analysts have adjusted their EPS Estimate for SAREPTA THERAPEUTICS INC with a 27.1% change. This highlights the evolving outlook on the company's EPS potential.
• The recent financial report of SAREPTA THERAPEUTICS INC demonstrates a 219.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• accelerating EPS growth for SAREPTA THERAPEUTICS INC: the current Q2Q growth of 219.0% exceeds the previous year Q2Q growth of 138.0%.

What else is there to say on the fundamentals of NASDAQ:SRPT?

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

Taking everything into account, SRPT scores 5 out of 10 in our fundamental rating. SRPT was compared to 571 industry peers in the Biotechnology industry. Both the profitability and the financial health of SRPT get a neutral evaluation. Nothing too spectacular is happening here. SRPT is not overvalued while it is showing excellent growth. This is an interesting combination.

Check the latest full fundamental report of SRPT for a complete fundamental analysis.

Our Lois Navellier screen will find you more ideas suited for growth investing.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.